Measurement of cystatin C in human urine by particle-enhanced turbidimetric immunoassay on an automated biochemistry analyzer

2013 ◽  
Vol 46 (12) ◽  
pp. 1128-1130 ◽  
Author(s):  
Konstantinos Makris ◽  
Efthimia Nikolaki ◽  
Konstantinos Nanopoulos ◽  
Konstantinos M. Pirgakis ◽  
Chrisostomos K. Maltezos
2000 ◽  
Vol 46 (2) ◽  
pp. 193-197 ◽  
Author(s):  
Borut Štabuc ◽  
Levin Vrhovec ◽  
Mirna Štabuc-Šilih ◽  
Tomaž Edvard Cizej

Abstract Background: Serum cystatin C, a cysteine protease inhibitor, has been suggested as a new marker of glomerular filtration rate (GFR). This study explored the possibility of replacing the creatinine clearance (CrCl) estimation of GFR with cystatin C in early detection of renal impairment in cancer patients on chemotherapy. Methods: Serum creatinine and cystatin C concentrations as well as 24-h CrCl were determined simultaneously in 72 cancer patients. Among them, 60 were treated with combined chemotherapy with cisplatin (CDDP). Creatinine was determined enzymatically with a spectrophotometric method. Serum cystatin C was determined by a particle-enhanced turbidimetric immunoassay. Results: Cystatin C and creatinine correlated significantly (P = 0.001) with CrCl. The correlation was significantly better for cystatin C than creatinine (r = 0.84 vs 0.74; P = 0.01). Stepwise regression analysis identified no differences for the correlations between cystatin C and CrCl in patients with or without metastases (r = 0.82 and 0.84, respectively) as well as before treatment and before the fourth cycle of chemotherapy (r = 0.70 and 0.75, respectively). A cystatin C cutoff concentration of 1.33 mg/L had 87% sensitivity and 100% specificity for detecting CrCl <78 mL/min. ROC analysis indicated that cystatin C was superior to serum creatinine for predicting CrCl <78 mL/min (P <0.04). Conclusions: Serum cystatin C is superior to serum creatinine for detection of decreased CrCl and potentially for the estimation of GFR in cancer patients independent of the presence of metastases or chemotherapy.


2012 ◽  
Vol 45 (4-5) ◽  
pp. 339-344 ◽  
Author(s):  
Azita Sohrabian ◽  
Feria Hikmet Noraddin ◽  
Mats Flodin ◽  
Annika Fredricsson ◽  
Anders Larsson

2012 ◽  
Vol 26 (5) ◽  
pp. 358-364 ◽  
Author(s):  
Feria Hikmet Noraddin ◽  
Mats Flodin ◽  
Annika Fredricsson ◽  
Azita Sohrabian ◽  
Anders Larsson

2010 ◽  
Vol 58 (1) ◽  
pp. 59-67 ◽  
Author(s):  
Paweł Jonkisz ◽  
Krisztina Kungl ◽  
Agnieszka Sikorska ◽  
Agnieszka Kurosad ◽  
Józef Nicpoń

Cystatin C is a serum protein with low molecular mass, which has been suggested as a marker to assess renal function in the dog. This protein is regularly assessed using particle-enhanced turbidimetric immunoassay (PETIA) and particle-enhanced nephelometric immunoassay (PENIA), in which rabbit anti-human cystatin C antibodies are used. The purpose of this work was to compare the results of cystatin C analysis obtained by PETIA and PENIA assays in the dog. Forty dogs of different genders and breeds were classified into four groups of 10 animals each based on serum creatinine concentrations (4 stages of chronic kidney disease). Serum cystatin C concentration was measured using PETIA and PENIA assays, the results were compared, and correlation with serum urea and creatinine concentrations was established. The correlation coefficient for results obtained using PETIA and PENIA assays was r = 0.706. Serum cystatin C concentrations obtained in PETIA had a lower correlation coefficient with creatinine concentrations than those found in PENIA (r = 0.614 and r = 0.904, respectively); similarly, serum cystatin C was less correlated with serum urea concentration in PETIA than in PENIA (r = 0.463 and r = 0.636, respectively). The results obtained in this study suggest that the nephelometric assay is more sensitive and was shown to be more closely correlated with other renal function indicators than the PETIA assay.


2020 ◽  
Vol 177 ◽  
pp. 112889
Author(s):  
Amanda Suárez-Fernández ◽  
Ana González-Antuña ◽  
Pablo Rodríguez-González ◽  
J. Ignacio García Alonso

2009 ◽  
Vol 877 (8-9) ◽  
pp. 747-750 ◽  
Author(s):  
Othman Ibrahem Yousef Al-Musaimi ◽  
Manar Khalid Fayyad ◽  
Adel Khalil Mishal

1997 ◽  
Vol 43 (6) ◽  
pp. 1016-1022 ◽  
Author(s):  
Hazel Finney ◽  
David J Newman ◽  
Walter Gruber ◽  
Peter Merle ◽  
Christopher P Price

Abstract Serum cystatin C has been suggested as a new marker of glomerular filtration rate (GFR). We describe a fully automated and rapid particle-enhanced nephelometric immunoassay (PENIA) for measuring serum cystatin C on the Behring nephelometer systems (BNA, BN II). Each sample is analyzed in 6 min with as many as 75 samples per batch. The assay covers the range 0.23–7.25 mg/L, up to seven times the upper limit of normal. The intra- and interassay imprecision are <3.3% and <4.5%, respectively. There is absolute linearity across the assay range (r2 = 0.997), with analytical recovery by cystatin C addition between 95% and 109% (mean 102%). Hemoglobin (≤8.0 g/L), bilirubin (≤488 μL), triglycerides (≤23 mmol/L), rheumatoid factor (≤2000 kIU/L), and myeloma paraprotein (≤41 g/L) do not interfere with the assay. This assay agreed well with an in-house particle-enhanced turbidimetric immunoassay (PETIA) (mean difference = 1.73 ± 2.10) and a commercial PETIA (mean difference = 1.13 ± 0.86). This is a new assay by which cystatin C may be effectively used as a marker of GFR estimation.


2006 ◽  
Vol 5 (1) ◽  
pp. 145-145
Author(s):  
A VAZIR ◽  
A BOLGER ◽  
C LOONG ◽  
T AGUSTSSON ◽  
H PENSTON ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document